Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CEL | P19835 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15687733 | 0.98 | TDO2 (0.41) | TDO2BACE1CELTDP1HRH4 | |
| SCHEMBL31314212 | 0.96 | TDO2 (0.35) | TDO2BACE1TDP1FEN1TAAR1 | |
| SCHEMBL31314110 | 0.92 | TDP1 (0.35) | TDP1TAAR1 | |
| SCHEMBL21746571 | 0.84 | PIK3CB (0.32) | TDP1TAAR1 | |
| SCHEMBL29986193 | 0.80 | TDP1 (0.40) | TDO2CELTDP1GCGRGRM2 | |
| SCHEMBL1202161 | 0.80 | TDP1 (0.40) | TDO2CELTDP1GCGRGRM2 | |
| SCHEMBL10845597 | 0.78 | TDP1 (0.39) | TDO2CELTDP1GCGRGRM2 | |
| SCHEMBL29987339 | 0.78 | TDP1 (0.39) | TDO2CELTDP1GCGRGRM2 | |
| SCHEMBL2647857 | 0.76 | TDP1 (0.40) | CELTDP1 | |
| SCHEMBL31524176 | 0.76 | TDP1 (0.40) | CELTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-0781283-B1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-06-06 | — | — | EP | disclosed |
| CN-1158130-A | Triazolopyridazines, their preparation and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-08-27 | — | — | CN | disclosed |
| EP-0781283-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008496-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | TDO2 4369/4885BACE1 4395/4885CEL 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.